Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03131388 · ClinicalTrials.gov registry record
Clinical Performance Evaluation of AMH Assay
A clinical trial, sponsored by Beckman Coulter.
- Completed
- Registry status
- 277
- Enrollment target
NCT03131388: Completed study, sponsored by Beckman Coulter.
NCT03131388 is a clinical trial that has completed, run by Beckman Coulter. The registered enrollment target is 277 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03131388 has completed, sponsored by Beckman Coulter.
- COMPLETED
- Registry status
- 277 participants
- Enrollment target
Study Summary
The Access AMH Assay is an in vitro diagnostic assay intended as an aid for fertility assessment. The purpose of the study is to evaluate the clinical performance of the Access AMH Assay in the intended use population.
Primary Outcome
Comparison of AMH levels in women at different levels of AFC to aid in assessing ovarian reserve
Interventions
- DIAGNOSTIC_TEST Access AMH Assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 277 participants |
| Start Date | 2016-09 |
| Est. Completion | 2018-04-30 |
What the finished NCT03131388 record still lists
NCT03131388 is an observational study that tracks outcomes without assigning an intervention. The registered 277 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Access AMH Assay is the first listed.
NCT03131388 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03131388 about?
NCT03131388 is a clinical study titled "Clinical Performance Evaluation of AMH Assay". The Access AMH Assay is an in vitro diagnostic assay intended as an aid for fertility assessment. The purpose of the study is to evaluate the clinical performance of the Access AMH Assay in the intended use population.
What is the current status of trial NCT03131388?
This trial is currently completed. The enrollment target is 277 participants. The study started on 2016-09. Estimated completion is 2018-04-30.
What interventions are being tested in trial NCT03131388?
The interventions under investigation include: Access AMH Assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03131388?
This trial is sponsored by Beckman Coulter, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05818683 · 277 participants · Phase 1
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
- NCT06789913 · 277 participants · Phase 2
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
- NCT04586959 · 278 participants · NA
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
- NCT05010148 · 278 participants · Phase 3
A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia